Home | Contact us | Disclaimer
MEDIA center
Transition Therapeutics Research Day 2014


ELND005 Phase II Clinical Study Data in Alzheimer's Disease

  • Safety and Efficacy Results of a Phase 2 Randomized, Placebo-Controlled, Dose-Ranging Study of ELND005 (Scyllo-inositol) in Mild to Moderate Alzheimer’s Disease
    Stephen Salloway et al.
    [Original ICAD poster] [Reformatted version]
  • Imaging & Cerebrospinal Fluid Biomarker Results of a Phase 2 Dose-Ranging Study of ELND005 (Scyllo-inositol) in Mild/Moderate AD
    Dr. Anton Porsteinson, William B and Sheila Konar on behalf of ELND005-AD201 investigators
    [ICAD presentation]
  • Population Pharmacokinetic Analysis of Plasma, Cerebrospinal Fluid, and Brain ELND005 in Patients with Mild to Moderate Alzheimer’s Disease
    Earvin Liang et al.
    [Original ICAD poster] [Reformatted version]
  • A Phase 2 randomized trial of ELND005, scyllo-inositol, in mild-moderate Alzheimer’s disease
    Salloway et al., Neurology, September 27, 2011 issue
    [Link to Neurology]

© 2013 Transition Therapeutics Inc.

Warning: file_get_contents(http://api.ipinfodb.com/v2/ip_query.php?key=7464f46d24567583aaafe0c69105fff4acf5121061d53fdd919462e3d1502625&ip=54.205.168.88&timezone=false) [function.file-get-contents]: failed to open stream: HTTP request failed! in /opt/apache/hosts/www.transitiontherapeutics.com/media/presentation.php on line 97

Warning: DOMDocument::loadXML() [function.DOMDocument-loadXML]: Empty string supplied as input in /opt/apache/hosts/www.transitiontherapeutics.com/media/presentation.php on line 98